Loading...
Current cholesterol guidelines recommend a high-intensity statin as initial therapy for patients with atherosclerotic cardiovascular disease (ASCVD). To understand whether moderate-intensity statin plus ezetimibe combination therapy yielded similar outcomes to high-intensity statin therapy alone, these authors performed a randomized, open-label, noninferiority trial. They randomized 3780 patients with ASCVD from 26 clinical centers in South Korea to receive either combination lipid-lowering therapy with moderate-intensity statin plus ezetimibe (rosuvastatin 10 mg; ezetimibe 10 mg) or high-intensity statin monotherapy (rosuvastatin 20 mg). The study was funded by a company that makes rosuvastatin-ezetimibe combination tablets.
During 3 years …